Drug Trial Radar · NCT06073665
Dosing of LT4 in Older Individuals
Last checked: Nov 20, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
228
Planned (sponsor's estimate)
Start
Jan 31, 2024
Primary completion
Apr 1, 2028
Study completion Apr 1, 2028
Sponsor
- Lead sponsor
- University of PennsylvaniaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Our overall goal is to determine the clinical consequences of allowing greater flexibility in LT4 dosing in older individuals who take LT4.
Conditions
- Hypothyroidism
Interventions
Levothyroxine SodiumDrug
Levothyroxine dose will depend on dose at baseline and randomization group
Primary outcomes
What the sponsor says the trial is designed to measure.
- Thyroid-Related Quality of Life Patient-Reported Outcome Quality of Life scaleTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Penn Medicine, Smilow Translational Research Center
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.